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Background: Of the estimated 800,000 adults living with HIV in Zambia in 2011, roughly half were receiving
antiretroviral therapy (ART). As treatment scale up continues, information on the care provided to patients after
initiating ART can help guide decision-making. We estimated retention in care, the quantity of resources utilized,
and costs for a retrospective cohort of adults initiating ART under routine clinical conditions in Zambia.
Methods: Data on resource utilization (antiretroviral [ARV] and non-ARV drugs, laboratory tests, outpatient clinic
visits, and fixed resources) and retention in care were extracted from medical records for 846 patients who initiated
ART at ≥15 years of age at six treatment sites between July 2007 and October 2008. Unit costs were estimated from
the provider’s perspective using site- and country-level data and are reported in 2011 USD.
Results: Patients initiated ART at a median CD4 cell count of 145 cells/μL. Fifty-nine percent of patients initiated on
a tenofovir-containing regimen, ranging from 15% to 86% depending on site. One year after ART initiation, 75% of
patients were retained in care. The average cost per patient retained in care one year after ART initiation was $243
(95% CI, $194-$293), ranging from $184 (95% CI, $172-$195) to $304 (95% CI, $290-$319) depending on site. Patients
retained in care one year after ART initiation received, on average, 11.4 months’ worth of ARV drugs, 1.5 CD4 tests,
1.3 blood chemistry tests, 1.4 full blood count tests, and 6.5 clinic visits with a doctor or clinical officer. At all sites,
ARV drugs were the largest cost component, ranging from 38% to 84% of total costs, depending on site.
Conclusions: Patients initiate ART late in the course of disease progression and a large proportion drop out of care
after initiation. The quantity of resources utilized and costs vary widely by site, and patients utilize a different mix
of resources under routine clinical conditions than if they were receiving fully guideline-concordant care. Improving
retention in care and guideline concordance, including increasing the use of tenofovir in first-line ART regimens,
may lead to increases in overall treatment costs.
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Of the estimated 800,000 adults living with HIV in
Zambia in 2011, roughly half were receiving antiretro-
viral therapy (ART) [1,2]. The Government of Zambia
revised national HIV treatment guidelines for adults in
2007 to recommend the use of tenofovir as a standard
component of first-line ART [3]. Guidelines were revised
again in 2010 to raise the CD4 cell count threshold for
ART eligibility from 200 cells/μL to 350 cells/μL and
again in 2013 to remove any CD4 cell count threshold
for ART eligibility for pregnant women [4,5]. Each of
these changes substantially increased either the number
of patients eligible for treatment or the cost of the drugs
that comprise the treatment.
As treatment scale up continues, and as the Govern-
ment of Zambia considers further guidelines changes
that could expand ART eligibility even more or affect
the quality of care for patients already on ART, informa-
tion about the actual care provided to patients after initi-
ating ART in Zambia can help guide decision making.
Published papers have reported on the positive clinical
and programmatic outcomes for patients initiating ART
in Zambia [6,7] and on the costs of providing ART in
Zambia [8,9], but no published papers have described
both the actual care provided by the public sector clinics
and hospitals that serve the vast majority of patients and
the associated costs at the patient level. Our objective
was to estimate retention in care, the quantity of re-
sources utilized, and costs for adults initiating treatment
under routine clinical conditions in Zambia.Methods
Analytic overview
We enrolled a retrospective cohort of HIV-infected
adults who initiated ART at six treatment sites in
Zambia between July 2007 and October 2008, after
tenofovir replaced stavudine in national guidelines as a
standard component of first-line antiretroviral therapy.
We collected patient-level data on retention in care
and resource utilization from outpatient medical re-
cords. We estimated site- and country-level data on
unit costs from financial reports, procurement records,Table 1 Study site characteristics
Characteristic Site 1 Site 2 Site 3







Setting Urban Urban Urban
Number of active patients enrolled
in ART program, 2008
5,488 5,102 1,167
ART: antiretroviral therapy.
aFirst-level hospitals are district-level hospitals. Second-level hospitals are larger, proand other sources. We estimated the proportion of pa-
tients retained in care, the average quantity of re-
sources utilized per patient and per patient retained in
care, and the average cost per patient and per patient
retained in care through one year after ART initiation
at all six sites and through two and three years after
ART initiation at two of the six sites (where additional
data were available at the time of data collection). We
included resources utilized and costs incurred at the
treatment site only; off-site resource utilization and
costs were excluded. Costs were calculated from the
provider’s perspective in 2011 US dollars.Study sites
Large scale, public sector provision of ART in Zambia
began in Lusaka in 2004 and rapidly expanded. At the
time of this study, clinics and hospitals across the coun-
try were providing ART, laboratory tests, and medica-
tions for opportunistic infections to patients free of
charge. We purposively selected six of these sites to
illustrate different models or settings for adult ART de-
livery in Zambia (Table 1). Sites included two primary
health clinics in Lusaka Province (sites 1 and 2), a pri-
mary health clinic in Copperbelt Province (site 3), a
second-level general hospital in Western Province (site
4), a first-level district hospital in Southern Province
(site 5), and a second-level mission hospital in Southern
Province (site 6). The number of active patients enrolled
in the ART program at each site in 2008 ranged from
524 at site 5 to 5,748 at site 4.
At the time of this study, ART eligibility, recom-
mended ART regimens, and schedules for laboratory
and clinical monitoring were in accordance with the
2007 national HIV treatment guidelines [3]. When CD4
testing was available, patients were eligible to initiate
ART if they had (1) a CD4 < 200 cells/μL, (2) a CD4 <
350 cells/μL with a WHO clinical stage 3 disease, or
(3) a WHO clinical stage 4 disease. When CD4 testing
was not available, patients were eligible to initiate ART if
they had (1) a WHO clinical stage 3 or 4 disease or (2) a
WHO clinical stage 2 disease and a total lymphocyte
count <1200 cells/μL. Guidelines recommended a first-Site 4 Site 5 Site 6









vincial-level or general hospitals.
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and either efavirenz or nevirapine, with abacavir and
lamivudine substituted for tenofovir and emtricitabine
for patients with low creatinine clearance. Guidelines
also recommended at least two CD4, hemoglobin, white
blood cell count, and blood chemistry tests and at least
five clinic visits during the first year on ART.
Sample enrollment
Adults who initiated ART at least 12 months prior to
data collection at sites 1, 3, 4, and 5, and at least
36 months prior to data collection at sites 2 and 6, were
selected consecutively from clinic registers and enrolled
in the study. Data collection at sites 2 and 6 occurred
after data collection at the other sites. Patients at sites 2
and 6 therefore had a longer follow-up period than pa-
tients at the other sites because additional data were
available at the time of data collection.
Patients were eligible for enrollment if they were at
least 15 years of age at the time of ART initiation and
were not known to have transferred to another clinic
during the study follow up period. The target enrollment
at each site was 150 patients. Fewer patients were en-
rolled at site 5 due to low patient volume. Seven pa-
tients, one each at sites 1, 2, 4, and 5, and three at site 3,
were excluded after enrollment because they were found
not to meet all study inclusion criteria. Total enrollment
was therefore 846 patients.
Ethics statement
The Boston University Medical Center Institutional Review
Board and the University of Zambia Biomedical Research
Ethics Committee provided ethical approval of the study
(protocol numbers H-28282 and 003-06-07). A waiver of
informed consent was granted by both committees because
the study was a retrospective review of routinely collected
information from patient medical records.
Data collection
Data on patient outcomes and resources utilized at the
treatment site during the first 12 or 36 months following
ART initiation were obtained from each study patient’s
medical record. All resources used by the provider to de-
liver outpatient care to study patients were included,
even if the resource cost was borne by another entity.
Data on the costs of resources utilized were collected
from site-level financial records, interviews with site
managers, and country-level drug price lists and pro-
curement records.
Classification of patient outcomes
Study patients at all sites were assigned outcomes at
12 months after initiating ART. Patients at sites 2 and 6
were also assigned outcomes at 24 and 36 months afterinitiating ART. Patients were classified as known to have
died if a confirmation of death was noted in their medical
record before the 12-, 24-, or 36-month endpoint. Patients
were classified as lost to follow up if they were ≥3 months
late for their last scheduled consultation or medication
pickup before the endpoint but had no confirmation of
death in their medical record. Patients not classified as
known to have died or lost to follow up were classified as
retained in care.Estimation of unit costs
We used previously published methods to estimate unit
costs for fixed and variable resources utilized at the treat-
ment sites by study patients, as outlined in Table 2 [10-13].
Fixed resources included buildings, equipment, and sup-
port staff employed in the ART clinic who do not see pa-
tients. Variable resources included ARV drugs, non-ARV
drugs, laboratory tests, and provider time for clinic visits.
Costs estimated in Zambian Kwacha (ZMK) were first
adjusted to 2011 levels, if necessary, using the consumer
price index and then converted to US dollars at a rate of
4,861 ZMK/$, the average exchange rate for 2011
[14,15]. We excluded costs of resources used for in-
patient care and resources used for outpatient care
above the level of the treatment site, such as government
or NGO costs of oversight or training. We also excluded
costs of resources procured by individual patients, such
as transport to the clinic, and costs of resources used
prior to ART initiation.Average resource utilization and costs
We calculated the total quantity of each resource uti-
lized by each patient and then calculated total costs for
each patient by multiplying the unit cost for each re-
source by the total quantity utilized. We calculated
average resource utilization and costs by dividing total
resource utilization and costs for all patients by the total
number of patients in the cohort. We repeated the same
calculations for the subset of patients retained in care
12 months after initiating ART. At sites 2 and 6, where
we had 36 months of follow up for each patient, we also
calculated the average annual cost for the subset of pa-
tients retained in care 24 and 36 months after initiating
ART by estimating the average cost for these patients
over the first two or three years on ART and then divid-
ing by two or three years.
We calculated average resource utilization and costs
for each of sites 1 through 6 alone, as well as for sites 1
through 6 combined. The confidence intervals for the
means for the six sites combined were adjusted for clus-
tering at the site level (using the cluster option with the
regression command in Stata).





Estimated upfront investment costs using a replacement cost approach, then calculated annualized costs using a 3% annual
discount rate and an estimated working life of 5 years for equipment and 50 years for buildings [11]. Annual building and
equipment costs for the ART clinic at each site were divided by the total number of active HIV patients at the site per year to
estimate a cost per patient-year in care. The total number of active HIV patients at the site was calculated by summing the
number of ART patients at the site with the number of non-ART patient-equivalents weighted based on a ratio of the average
number of patient visits to the site per year for non-ART versus ART patients.
Support staff Estimated annual cost of support staff employed in the ART clinic at the study sites during the study period based on 2011
salaries and allowances. The proportion of staff time allocated to ART versus non-ART activities was based on staff estimates.
Annual support staff costs were divided by the total number of active HIV patients at the site per year to estimate a cost
per patient-year in care. The total number of active HIV patients at the site was calculated by summing the number of ART
patients at the site with the number of non-ART patient-equivalents weighted based on a ratio of the average number of
patient visits to the site per year for non-ART versus ART patients. Costs for higher-level administrative support staff, including
staff based in the health facility in which the ART clinic was located, were excluded from the analysis.
Variable resources
ARV drugs Estimated as the average per unit cost for all units of a particular drug purchased for the Zambia national HIV program in
2011, or during the most recent year available if no units of a particular drug were purchased in 2011, as recorded in the
Global Price Reporting Mechanism [12]. Data on ART regimen dispensed were used to determine the appropriate drug
formulation (fixed dose tablet, single dose tablet) for each ARV drug dispensed [3].
Non-ARV drugs Estimated from standard Zambian Ministry of Health per package costs [13].
Laboratory tests For sites 3, 4, 5, and 6, where laboratory tests are run onsite, costs were estimated as the sum of unit costs for reagents,
consumables, equipment, labor, and space. Costs of reagents and consumables were estimated from standard Zambian
Ministry of Health per package costs [13]. Annual laboratory equipment, labor, and space costs were divided by the total
number of laboratory tests performed per year to estimate a per test cost at each site. For sites 1 and 2, where laboratory
tests are run at a centralized laboratory, costs were provided by the Centre for Infectious Disease Research in Zambia Central
Laboratory in Lusaka and included the cost of reagents, consumables, equipment, and labor used for each test (Henry Latner,
personal communication, April 29, 2011).
Provider time for
clinic visits
Estimated the total annual cost of staff time for each type of provider conducting patient consultations. The proportion of
staff time allocated to ART versus non-ART activities was based on staff estimates. Cost per visit was calculated by dividing
the total cost of staff time for each type of provider, valued at 2011 salaries and allowances, by the total number of patient
consultations with each provider type per calendar year.
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Cohort characteristics
Patients initiated ART at a median age of 35 years and a
median CD4 cell count of 145 cells/μL; 60% of patients
were female (Table 3). The majority of patients (59%)
initiated on regimens containing tenofovir while the re-
mainder initiated on zidovudine (14%), abacavir (14%),Table 3 Cohort characteristics
Characteristic Site 1 Site 2
Total sample size 149 149
Follow up time, months 12 36
Median age at ART initiation, years [IQR] 35 [30–40] 35 [30–43]
Sex, % female 63 52
Median CD4 at ART initiation, cells/μL [IQR]a 149 [97–211] 127 [67–206] 1
Regimen at ART initiation, % of patients
TDF-containing regimen 36 86
AZT-containing regimen 30 5
ABC-containing regimen 0 5
d4T-containing regimen 34 5
ART: antiretroviral therapy; ABC: abacavir; AZT: zidovudine; d4T: stavudine; IQR: inte
a793 of 846 patients in the sample had a CD4 cell count at initiation.and stavudine (13%). ART regimen at initiation varied
widely by site.
Patient outcomes
One year after ART initiation, 75% of patients were
retained in care, 11% were known to have died, and 15%
were lost to follow up (Table 4). The proportion ofSite 3 Site 4 Site 5 Site 6 All sites
147 149 102 150 846
12 12 12 36 —
34 [29–40] 33 [29–42] 35 [31–41] 37 [31–46] 35 [30–42]
68 66 45 58 60
36 [84–199] 150 [77–237] 140 [74–273] 160 [106–209] 145 [86–212]
80 15 54 80 59
13 4 30 7 14
0 76 0 0 14
7 5 16 13 13
rquartile range; TDF: tenofovir.
Table 4 Retention in care one year after initiating antiretroviral therapy
Patient outcome, n (%) Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 All sites
Retained in care 116 (78) 103 (69) 109 (74) 116 (78) 76 (75) 113 (75) 633 (75)
Known to have died 13 (9) 23 (15) 14 (10) 7 (5) 6 (6) 26 (17) 89 (11)
Lost to follow up 20 (13) 23 (15) 24 (16) 26 (17) 20 (20) 11 (7) 124 (15)
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pending on site.
At sites 2 and 6, where patients were followed for
three years after ART initiation, retention in care de-
creased from 69% and 75% one year after initiating ART
to 64% and 72% two years after initiating ART and 61%
and 64% three years after initiating ART. For patients
retained in care one year after initiating ART at sites 2
and 6, the probability of being retained in care two years
after initiating ART was 93%. For patients retained in
care two years after initiating ART, the probability of be-
ing retained in care three years after initiating ART was
92%. The proportion of patients known to have died was
18% two and three years after initiating ART.
Resource utilization
During the first year after ART initiation, patients uti-
lized, on average, 9.1 months’ worth of NRTI drugs and
9.0 months’ worth of NNRTI drugs or protease inhibitor
(PI) drugs (Table 5). Patients also utilized, on average,
5.2 months’ worth of co-trimoxazole, 1.2 CD4 tests, 1.1
blood chemistry tests, 1.2 full blood count tests, 5.4
clinic visits with a doctor or clinical officer, and 7.9 visits
with a pharmacist.
As expected, patients retained in care one year after
initiating ART utilized substantially more resources than
those known to have died or lost to follow up, including
11.4 months’ worth of NRTIs and 11.2 months’ worth of
NNRTIs or PIs, 6.5 months’ worth of co-trimoxazole,
1.5 CD4 tests, 1.3 blood chemistry tests, 1.4 full blood
count tests, 6.5 clinic visits with a doctor or clinical offi-
cer, and 9.5 visits with a pharmacist. The quantity of
each resource utilized varied widely by site.
Unit costs
ARV drug costs, which were constant across sites, varied
by drug regimen (Table 6). Abacavir and tenofovir were
more expensive than zidovudine and stavudine, and efa-
virenz was more expensive than nevirapine. The cost of
co-trimoxazole was modest compared to the cost of
ARV drugs.
Laboratory test costs varied widely between sites. The
cost per CD4 test, for example, ranged from $2.87 at
sites 1 and 2, where tests were run at a centralized,
high-volume laboratory in Lusaka, to $18.16 at site 5
where tests were run onsite at a relatively low-volume
laboratory. The cost per clinic visit with each type ofprovider and the cost of fixed resources per month in
care also varied widely between sites.
Average cost per patient
During the first year after ART initiation, the average
cost per patient for the total sample was $198 (95% CI,
$157-$239), ranging from $151 (95% CI, $137-$165) at
site 1 to $251 (95% CI, $229-$273) at site 5 (Table 7).
The average cost per patient for the subset of the sample
remaining in care one year after initiating ART was $243
(95% CI, $194-$293), ranging from $184 (95% CI, $172-
$195) at site 1 to $304 (95% CI, $290-$319) at site 5.
At sites 2 and 6, where patients were followed for
three years after ART initiation, the average annual cost
per patient remaining in care decreased from $245
(95% CI, $235-$254) and $296 (95% CI, $285-$307) one
year after initiating ART to $233 (95% CI, $221-$245)
and $272 (95% CI, $262-$282) two years after initiating
ART and $221 (95% CI, $208-$234) and $270 (95% CI,
$260-$279) three years after initiating ART. Decreases in
the cost per patient remaining in care over time are due
primarily to decreases in the quantity of resources uti-
lized over time.
Antiretroviral drugs were the largest cost component
at all six sites, comprising between 38% (site 5) and 84%
(site 4) of the average cost per patient for the subset of
the sample remaining in care one year after initiating
ART.
Discussion
The Government of Zambia revised national HIV treat-
ment guidelines in 2007 to recommend the use of teno-
fovir as a standard component of first-line ART and in
2010 and 2013 to expand eligibility criteria for patients
not yet on ART [3-5]. As the Government of Zambia
considers new guidelines changes, with potentially large
implications for program planning and budgets, infor-
mation on the actual care provided under previous
guidelines can help guide decision making. We used pri-
mary, patient-level data to estimate retention in care, the
quantity of resources utilized, and the costs of providing
ART to adults in routine clinical practice in Zambia
after adoption of the 2007 national guidelines.
Patients initiated ART at a median CD4 cell count of
145 cells/μL; 59% initiated on a tenofovir-containing
regimen. One year after ART initiation, 75% of patients
were retained in care. Patients retained in care received,
Table 5 Average quantity of resources utilized per patient during the first year on antiretroviral therapy
Resource Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 All sites
Quantity of resources utilized per patient for total sample
ARV drugs, number of patient-months
NRTI combinations
TDF 300 mg + FTC 200 mg 3.7 7.6 7.3 1.3 4.1 8.8 5.6
AZT 300 mg + 3TC 150 mg 2.6 0.0 0.8 0.5 2.2 1.0 1.1
ABC 300 mg + 3TC 150 mg 0.1 0.9 0.0 6.4 0.0 0.1 1.3
d4T 30 mg + 3TC 150 mg 2.5 0.6 0.6 0.5 1.4 1.1 1.1
Any NRTI combination 8.9 9.1 8.8 8.7 7.8 11.1 9.1
NNRTI or PI
NVP 200 mg 6.4 7.7 4.0 2.5 3.7 4.0 4.8
EFV 600 mg 2.2 1.5 4.5 6.2 4.0 6.8 4.2
LPV/r 200/50 mg 0.1 0.0 0.0 0.0 0.0 0.0 0.0
Any NNRTI or PI 8.8 9.2 8.5 8.6 7.7 10.8 9.0
Non-ARV drugs, number of patient-monthsa
Co-trimoxazole 400/80 mg 6.4 8.8 1.3 3.2 0.2 9.8 5.2
Laboratory tests, number of testsb
CD4 test 1.5 1.3 1.4 0.5 1.5 1.2 1.2
Blood chemistry testc 0.2 1.9 1.0 0.3 1.0 2.2 1.1
Full blood countd 1.3 1.2 1.0 0.4 2.0 1.3 1.2
Clinic visits with each type of provider, number of visitse
Doctor or clinical officer 5.0 5.3 5.3 3.4 6.6 7.4 5.4
Nurse 7.4 6.8 5.4 4.2 6.6 7.4 6.3
Counselor 9.2 9.2 6.1 7.6 6.6 6.6 7.6
Pharmacist 9.5 10.0 6.1 7.2 6.6 7.3 7.9
Fixed resources, number of patient-monthsf 9.9 9.3 9.6 10.1 9.6 9.8 9.7
Quantity of resources utilized per patient for subset of sample retained in care one year after initiating ART
ARV drugs, number of patient-months
NRTI combinations
TDF 300 mg + FTC 200 mg 4.3 10.2 9.3 1.6 5.1 10.8 6.9
AZT 300 mg + 3TC 150 mg 3.3 0.0 1.0 0.6 2.9 1.3 1.5
ABC 300 mg + 3TC 150 mg 0.1 1.2 0.0 7.6 0.0 0.1 1.6
d4T 30 mg + 3TC 150 mg 3.1 0.9 0.8 0.5 1.7 1.4 1.4
Any NRTI combination 10.9 12.2 11.1 10.4 9.6 13.6 11.4
NNRTI or PI
NVP 200 mg 7.9 10.3 5.1 2.9 4.6 5.1 6.0
EFV 600 mg 2.6 2.0 5.6 7.4 5.0 8.1 5.2
LPV/r 200/50 mg 0.2 0.0 0.0 0.0 0.0 0.0 0.0
Any NNRTI or PI 10.7 12.3 10.7 10.2 9.6 13.2 11.2
Non-ARV drugs, number of patient-monthsa
Co-trimoxazole 7.9 11.8 1.6 3.8 0.3 12.1 6.5
Laboratory tests, number of testsb
CD4 test 1.8 1.9 1.6 0.6 1.7 1.5 1.5
Blood chemistry testc 0.1 2.5 1.0 0.3 1.0 2.6 1.3
Full blood countd 1.6 1.6 1.0 0.5 2.2 1.6 1.4
Scott et al. BMC Public Health 2014, 14:296 Page 6 of 11
http://www.biomedcentral.com/1471-2458/14/296
Table 5 Average quantity of resources utilized per patient during the first year on antiretroviral therapy (Continued)
Clinic visits with each type of provider, number of visitse
Doctor or clinical officer 5.9 6.6 6.4 3.8 8.0 8.7 6.5
Nurse 8.8 8.6 6.5 4.8 8.0 8.7 7.5
Counselor 11.1 11.9 7.4 8.9 8.0 7.8 9.2
Pharmacist 11.4 13.0 7.4 8.5 8.0 8.6 9.5
Fixed resources, number of patient-monthsf 12.0 12.0 12.0 12.0 12.0 12.0 12.0
3TC: lamivudine; ABC: abacavir; ART: antiretroviral therapy; ARV: antiretroviral; AZT: zidovudine; d4T: stavudine; EFV: efavirenz; FTC: emtricitabine; LPV/r: ritonavir-
boosted lopinavir; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NVP: nevirapine; PI: protease inhibitor;
TDF: tenofovir.
aPatients in our sample received other non-ARV drugs in addition to co-trimoxazole. These included, but were not limited to: multivitamins, folic acid supplements,
ferrous sulfate supplements, paracetamol, fluconazole, ibuprofen, and amoxicillin.
bIn addition to CD4 tests, blood chemistry tests, and full blood counts, patients in our sample also received <0.1 on average of each of the following lab tests
during the first year on ART: acid-fast bacillus, hepatitis B test, malaria test, pregnancy test, rapid plasma reagin test, and viral load test.
cA blood chemistry test could include any combination of the following tests: creatinine, aspartate aminotransferase, alanine aminotransferase, total bilirubin,
direct bilirubin, and urea.
dA full blood count includes hemoglobin and a white blood count, among other counts.
eA single clinic visit for patients in our sample could include a consultation with more than one type of provider (doctor or clinical officer, nurse, counselor,
or pharmacist).
fFixed resources included buildings and infrastructure, equipment, supplies, vehicles, and staff time for staff employed in the ART clinic who do not see patients.
Table 6 Unit costs (in 2011 USD) for resources utilized by adults receiving antiretroviral therapy
Resource Site 1 Site 2 Site 3 Site 4 Site 5 Site 6
ARV drugs, cost per patient-month dispensed
NRTI combinations
TDF 300 mg + FTC 200 mg 10.54 10.54 10.54 10.54 10.54 10.54
AZT 300 mg + 3TC 150 mg 8.41 8.41 8.41 8.41 8.41 8.41
ABC 300 mg + 3TC 150 mg 18.64 18.64 18.64 18.64 18.64 18.64
d4T 30 mg + 3TC 150 mg 3.01 3.01 3.01 3.01 3.01 3.01
NNRTI or PI
NVP 200 mg 2.34 2.34 2.34 2.34 2.34 2.34
EFV 600 mg 4.26 4.26 4.26 4.26 4.26 4.26
LPV/r 200/50 mg 36.70 36.70 36.70 36.70 36.70 36.70
Non-ARV drugs, cost per patient-month dispensed
Co-trimoxazole 400/80 mg 0.93 0.93 0.93 0.93 0.93 0.93
Laboratory tests, cost per testa
CD4 test 2.87 2.87 11.90 10.56 18.16 10.06
Blood chemistry test 2.93 2.93 5.01 7.23 5.11 2.27
Full blood count 2.80 2.80 2.14 5.24 5.60 1.11
Clinic visits with each type of provider, cost per visitb
Doctor or clinical officer visit 1.71 1.82 0.57 0.37 2.86 1.01
Nurse visit 0.52 1.01 0.48 0.40 1.91 0.59
Counselor visit 0.56 0.15 0.31 1.00 2.11 2.21
Pharmacist visit 0.42 0.32 0.29 0.45 1.50 0.28
Fixed resources, cost per month in carec 1.03 1.17 1.21 0.60 6.04 3.31
3TC: lamivudine; ABC: abacavir; ARV: antiretroviral; AZT: zidovudine; d4T: stavudine; EFV: efavirenz; FTC: emtricitabine; LPV/r: ritonavir-boosted lopinavir; NNRTI:
non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NVP: nevirapine; PI: protease inhibitor; TDF: tenofovir; USD: United
States Dollar.
aLaboratory tests for sites 1 and 2 were done at a centralized, high volume laboratory in Lusaka. Laboratory tests for sites 3, 4, 5, and 6 were done onsite.
bClinic visit costs include the cost of staff time for staff who see patients.
cFixed costs include the cost of buildings and infrastructure, equipment, supplies, vehicles, and staff time for staff employed in the ART clinic who do not
see patients.
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Table 7 Average costs and cost breakdown for the first year on antiretroviral therapy
Site 1 Site 2 Site 3 Site 4 Site 5 Site 6 All patients at all sitesd
Average cost, 2011 USD (95% CI)
Average cost per patient for total sample 151 (137–165) 185 (168–202) 166 (154–179) 209 (192–225) 251 (229–273) 242 (224–260) 198 (157–239)
Average cost per patient for subset of sample
retained in care one year after initiating ART
184 (172–195) 245 (235–254) 205 (198–212) 247 (233–261) 304 (290–319) 296 (285–307) 243 (194–293)
Breakdown of average cost per patient for subset of sample remaining in care one year after initiating ART, 2011 USD (% of total)
ARV drugsa 123 (67) 166 (68) 148 (72) 207 (84) 116 (38) 178 (60) 159 (66)
Non-ARV drugsa 12 (6) 20 (8) 4 (2) 5 (2) 0 (0) 22 (7) 11 (5)
Laboratory tests 11 (6) 18 (7) 27 (13) 11 (5) 49 (16) 23 (8) 22 (9)
Clinic visitsb 26 (14) 27 (11) 11 (5) 17 (7) 67 (22) 33 (11) 28 (11)
Fixed resourcesc 12 (6) 14 (6) 15 (7) 7 (3) 72 (24) 39 (13) 24 (9)
Total 184 (100) 245 (100) 205 (100) 247 (100) 304 (100) 296 (100) 243 (100)
ART: antiretroviral therapy; ARV: antiretroviral; CI: confidence interval; USD: United States Dollar.
aUnit costs for ARV and non-ARV drugs were standardized across all sites so variation in total ARV and non-ARV drug costs between sites are due to differences in utilization.
bClinic visits include the cost of staff time for staff who see patients.
cFixed costs include the cost of buildings and infrastructure, equipment, supplies, vehicles, and staff time for staff employed in the ART clinic who do not see patients.
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http://www.biomedcentral.com/1471-2458/14/296on average, 11.4 months’ worth of ARV drugs, 1.5 CD4
tests, 1.3 blood chemistry tests, 1.4 full blood count
tests, and 6.5 clinic visits with a doctor or clinical officer.
The average cost for all patients over the first year after
ART initiation was $198 (95% CI, $157-$239) while the
average cost per patient retained in care one year after
ART initiation was $243 (95% CI, $194-$293). Both the
average quantity of resources utilized and unit costs var-
ied widely by site, resulting in average costs per patient
retained in care ranging from $184 (95% CI, $172-$195)
at site 1 to $304 (95% CI, $290-$319) at site 5.
Our findings have several implications for program
planning. First, as has been widely reported throughout
Africa, Zambian patients are initiating ART late in the
course of disease progression [16]. The median CD4 cell
count at initiation for patients in our study, 145 cells/μL,
was considerably lower than the 200 cells/μL threshold
for ART eligibility in place at the time when these pa-
tients initiated ART [3]. This suggests that many pa-
tients may have reported to care long after meeting the
eligibility criteria for ART initiation. Future guidelines
changes that increase the CD4 threshold for ART eligi-
bility, and expand eligibility to a larger proportion of the
HIV-infected population, may have a smaller impact
than anticipated, both in terms of increased health bene-
fits and increased program costs, if patients are not ef-
fectively identified and linked to care soon after meeting
eligibility criteria.
Second, a large proportion of patients (25%) are no
longer in care within one year of initiating ART and at-
trition continues, at a slower rate, through three years
after initiating ART. The average cost per patient in our
sample for the first year on ART was $198. If we were to
estimate the average cost to produce a patient retained
in care one year after initiating ART, calculated as the
sum of all costs for all patients divided by just the num-
ber of patients remaining in care, it would be $265. If all
patients remained in care, we would expect an average
cost per patient of $243, greater than the average cost
per patient in the study of $198, but less than the cost to
produce a patient remaining in care of $265.
Third, actual resource utilization varied considerably
from what would be expected if patients were receiving
fully guideline-concordant care. At the time of this
study, guidelines recommended initiation on a regimen
containing tenofovir, emtricitabine, and either efavirenz
or nevirapine. Only 59% of patients in our sample initi-
ated ART on a tenofovir-containing regimen while the
remaining 41% of patients initiated ART on regimens
containing zidovudine, abacavir, or stavudine. Patients in
our sample initiated ART between July 2007 and October
2008, soon after tenofovir became the recommended first-
line ART regimen in Zambia. It is not known whether
study sites were still in the process of adopting tenofovirat the time of this study or if a similar mix of regimens
would be seen among patients initiating ART at the same
sites today. Nevertheless, these deviations from expected,
guideline-concordant utilization months after guidelines
were changed are notable.
Regardless of ART regimen at initiation, patients
retained in care one year after initiating ART received,
on average, fewer than the 12 months’ worth of ARV
drugs required to ensure uninterrupted treatment. These
patients also received only 1.5 CD4 tests, 1.3 blood
chemistry tests, and 1.4 full blood count tests during
their first year on ART. Guidelines recommend two
CD4 tests, at least two blood chemistry tests, and at least
two hemoglobin and white blood cell count tests, com-
ponents of a full blood count test, during the first year
after ART initiation [3]. While patients utilized fewer
drugs and laboratory tests than they would have under
fully guideline-concordant care, they had more frequent
clinical consultations than recommended by guidelines.
Patients retained in care had an average of 6.5 visits with
a doctor or clinical officer and 9.5 visits with a pharma-
cist during their first year on ART, compared to the five
visits recommended in the guidelines [3]. All of these ex-
amples suggest that it may not be appropriate to assume
that guidelines and practice will be identical for the pur-
poses of program planning and budgeting.
The proportion of patients retained in care one year
after ART initiation in our study, 75%, is comparable to
other published estimates of retention in care during the
first year on ART [16]. Our estimated cost of $243 per
patient retained in care one year after ART initiation is
lower than, but still comparable to, previously published
estimates of the cost per patient-year of ART in Zambia.
Tagar et al. estimated an average cost of $278 per
patient-year of ART (in 2010–2011) for a 30-site sample
by estimating total facility-level costs at each site during
the study period and dividing by an estimated number of
patient-years in care at each site during the same period
[17]. Bratt et al. estimated a cost per patient-year of
ART ranging from $278 to $523 (in 2008 US dollars) by
estimating unit costs from a 12-site sample and applying
the unit costs to a set of resources that patients would be
expected to utilize during their first year on ART under
idealized clinical care conditions [9]. Marseille et al. esti-
mated a cost of $428 per patient-year of ART in on-site
costs (in 2010 US dollars) for the average facility in their
45-site sample by applying unit costs to a mix of site- and
patient-level data on resource utilization [8]. The cost per
patient-year of ART was $638 when off-site costs were in-
cluded. Our study builds on these previous cost estimates
by: (1) providing insight into the actual quantity of re-
sources utilized and services received per patient at the
level of the treatment site, and (2) differentiating between
patients retained in care and those not retained.
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http://www.biomedcentral.com/1471-2458/14/296Our study has several limitations. First, results are
from six sites so we cannot attribute variation in costs of
care between sites to specific site-level characteristics.
These sites were purposively selected to capture vari-
ation in location and size. While results from these sites
provide insight into standard types of treatment sites in
Zambia, they are not necessarily representative of the
ART treatment program in Zambia as a whole. Second,
because patients were only classified as lost to follow up
if they were ≥3 months late for their last scheduled con-
sultation or medication pickup at the study endpoint, we
likely underestimate true attrition during the study fol-
low up period. Third, patient outcomes in this analysis
are limited to what could be ascertained from a retro-
spective review of medical records. For patients no lon-
ger attending the study clinic, we could not always
distinguish between those who had transferred to an-
other clinic, died, or been lost to follow up due to
incomplete records. Third, we excluded resource utiliza-
tion and costs associated with inpatient care and out-
patient care received prior to ART initiation. We also
excluded costs incurred by the patient and costs for pro-
gram management above the facility level. Cost esti-
mates from Marseille et al., who found that only $428 of
the $638 in total costs per patient-year of treatment
were incurred on site, suggest that this exclusion of costs
above the facility level may lead to a significant under-
estimate of the total cost of providing ART at the treat-
ment sites in our study sample. Finally, results reflect
retention in care, resource utilization, and costs for pa-
tients who initiated ART in 2007 and 2008, after the
adoption of tenofovir as a standard component of first-
line ART in 2007 but prior to the adoption of new HIV
treatment guidelines in 2010 that increased the CD4
threshold for ART eligibility from 200 cells/μL to 350
cells/μL and the announcement in 2013 that Zambia
would provide life-long ART to all pregnant women re-
gardless of CD4 cell count [4,5]. Both changes may lead
to a higher median CD4 cell count at initiation which
could, in turn, result in changes in retention in care, re-
source utilization, and costs.
Conclusions
In summary, adult patients in Zambia initiate ART late
in the course of disease progression and a large propor-
tion drop out of care within one year. Unit costs for each
resource and the average quantity of resources utilized
vary widely by treatment site, as do the resulting average
costs of care, suggesting opportunities for efficiency
gains. Overall, patients utilize a different mix of re-
sources under routine clinical conditions than if they
were receiving fully guideline-concordant care. The dif-
ferences between guidelines and practice highlight the
importance of looking at what is actually happening, andnot just what is expected to happen, to ensure effective
program planning and accurate budgeting. Improving
retention in care and guideline concordance, including
increasing the use of tenofovir in first-line ART regi-
mens, may lead to increases in overall treatment costs.
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